Table 3.

Adverse events that occurred at an incidence of ≥5%, adverse drug reactions that occurred at an incidence of ≥2% and adverse events that led to withdrawal at an incidence of ≥2% (excluding discolouration events caused by the iron contained in PA21) (safety set)

	PA21 group n = 108	Sevelamer group n = 105
Adverse events, n (%)	81 (75.0)	70 (66.7)
Nasopharyngitis	24 (22.2)	24 (22.9)
Diarrhoea	27 (25.0)	3 (2.9)
Constipation	2 (1.9)	19 (18.1)
Adverse drug reactions, n (%)	29 (26.9)	28 (26.7)
Diarrhoea	23 (21.3)	1 (1.0)
Constipation	0 (0.0)	19 (18.1)
Abdominal discomfort	0 (0.0)	3 (2.9)
Abdominal distension	0 (0.0)	3 (2.9)
Adverse events that led to withdrawal, n (%)	7 (6.5)	10 (9.5)
Diarrhoea	4 (3.7)	1 (1.0)
Constipation	0 (0.0)	3 (2.9)